Inhaled Mometasone Furoate Improves Health-Related Quality of Life in Patients with Persistent Asthma
Authors:
- Jill KarpelJKJill Karpel
- Anthony D'UrzoADAnthony D'Urzo
- Richard F. LockeyRLRichard F. Lockey
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 45 (9) , 747-753
Abstract
Results from two clinical trials of mometasone furoate administered via a dry powder inhaler (MF-DPI) were reviewed to evaluate the consistency of effects of MF-DPI administered once-daily in the evening (QD PM) or twice-daily (BID) on health-related quality of life (HRQOL) in adults with persistent asthma previously treated with inhaled corticosteroids. HRQOL data were collected from two 12-week, randomized, double-blind trials: in study 1 (n = 268), patients received MF-DPI 400 microg QD PM (1 inhalation), MF-DPI 200 microg BID, or placebo; in study 2 (n = 400), patients received MF-DPI 200 microg QD PM, MF-DPI 400 microg QD PM (1 inhalation), MF-DPI 200 microg BID, MF-DPI 400 microg QD PM (2 inhalations of 200 microg), or placebo. In both studies, HRQOL was assessed using the Medical Outcomes Survey 36-item Short Form (SF-36) and an asthma-specific module. MF-DPI was associated with consistent, statistically significant improvements in asthma-specific total scores, breathlessness, asthma concerns, and physical symptoms compared with placebo in both trials (p < 0.05 vs. placebo). MF-DPI improved SF-36 Physical Component Summary scores at all doses except 200 microg QD PM. In conclusion, the results from two placebo-controlled trials suggest that MF-DPI 400 microg/d, administered once or twice-daily, produces consistent, statistically, and clinically significant improvement in HRQOL measures in patients with persistent asthma.Keywords
This publication has 38 references indexed in Scilit:
- Patient preferences for managing asthma: results from a discrete choice experimentHealth Economics, 2007
- Once-daily evening administration of mometasone furoate in asthma treatment initiationAnnals of Allergy, Asthma & Immunology, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionateAnnals of Allergy, Asthma & Immunology, 2004
- Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel reportAnnals of Allergy, Asthma & Immunology, 2003
- Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparatorAnnals of Allergy, Asthma & Immunology, 2001
- Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionateAnnals of Allergy, Asthma & Immunology, 2001
- Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhalerAnnals of Allergy, Asthma & Immunology, 2001
- Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2000